Minimum important difference is minimally important in sample size calculations

Performing a sample size calculation for a randomized controlled trial requires specifying an assumed benefit (that is, the mean improvement in outcomes due to the intervention) and a target power. There is a widespread belief that judgments about the minimum important difference should be used when setting the assumed benefit and thus the sample size. This belief is misguided — when the purpose of the trial is to test the null hypothesis of no treatment benefit, the only role that the minimum important difference should be given is in determining whether the sample size should be zero, that is, whether the trial should be conducted at all. The true power of the trial depends on the true benefit, so the calculated sample size will result in a true power close to the target power used in the calculation only if the assumed benefit is close to the true benefit. Hence, the assumed benefit should be set to a value that is considered a realistic estimate of the true benefit. If a trial designed using a realistic value for the assumed benefit is unlikely to demonstrate that a meaningful benefit exists, the trial should not be conducted. Any attempt to reconcile discrepancies between the realistic estimate of benefit and the minimum important difference when setting the assumed benefit merely conflates a valid sample size calculation with one based on faulty inputs and leads to a true power that fails to match the target power. When calculating sample size, trial designers should focus efforts on determining reasonable estimates of the true benefit, not on what magnitude of benefit is judged important.